Cognition Therapeutics (NASDAQ:CGTX) Price Target Cut to $5.00 by Analysts at HC Wainwright

Cognition Therapeutics (NASDAQ:CGTX) had its price target reduced by HC Wainwright from $6.00 to $5.00 in a research report released on Monday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Cognition Therapeutics’ Q1 2025 earnings at ($0.12) EPS, Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.44) EPS, Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.07) EPS and FY2026 earnings at ($0.28) EPS.

Several other equities analysts also recently weighed in on CGTX. B. Riley raised shares of Cognition Therapeutics from a “neutral” rating to a “buy” rating and raised their price target for the stock from $1.00 to $1.50 in a research note on Thursday, December 19th. Chardan Capital decreased their target price on shares of Cognition Therapeutics from $11.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, March 21st. Finally, Brookline Capital Management upgraded Cognition Therapeutics to a “strong-buy” rating in a report on Monday, January 27th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $7.50.

Cognition Therapeutics Price Performance

Shares of Cognition Therapeutics stock opened at $0.44 on Monday. The business has a 50 day simple moving average of $0.57 and a two-hundred day simple moving average of $0.55. The stock has a market capitalization of $18.35 million, a P/E ratio of -0.46 and a beta of 1.03. Cognition Therapeutics has a 12 month low of $0.34 and a 12 month high of $2.95.

Cognition Therapeutics (NASDAQ:CGTX) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.01). During the same quarter in the previous year, the business earned ($0.27) earnings per share. As a group, research analysts anticipate that Cognition Therapeutics will post -0.8 EPS for the current fiscal year.

Institutional Investors Weigh In On Cognition Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC acquired a new position in Cognition Therapeutics in the 4th quarter valued at about $26,000. Two Sigma Investments LP raised its position in shares of Cognition Therapeutics by 372.2% during the 4th quarter. Two Sigma Investments LP now owns 53,691 shares of the company’s stock valued at $38,000 after buying an additional 42,321 shares during the period. Virtu Financial LLC acquired a new position in Cognition Therapeutics in the third quarter valued at approximately $27,000. Geode Capital Management LLC lifted its holdings in Cognition Therapeutics by 8.9% in the fourth quarter. Geode Capital Management LLC now owns 352,348 shares of the company’s stock valued at $247,000 after acquiring an additional 28,705 shares during the last quarter. Finally, Voss Capital LP purchased a new position in Cognition Therapeutics in the fourth quarter worth approximately $351,000. 43.35% of the stock is currently owned by institutional investors and hedge funds.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.